Literature DB >> 24511451

A review of therapeutic uses of mirtazapine in psychiatric and medical conditions.

Abdulkader Alam1, Zoya Voronovich1, Joseph A Carley1.   

Abstract

OBJECTIVE: To review the literature examining the use of mirtazapine with an emphasis on its therapeutic benefits for psychiatric patients with comorbid medical conditions. DATA SOURCES: MEDLINE, PsycINFO, Global Health, and AGRICOLA were searched using the terms mirtazapine OR Remeron. Limits were English language, human, year 1980-2012, treatment and prevention, and therapy. STUDY SELECTION: Two hundred ninety-three articles were identified. DATA EXTRACTION: Identified articles were reviewed with a focus on indications and therapeutic benefits in patients with medical comorbidities.
RESULTS: Mirtazapine is an effective antidepressant with unique mechanisms of action. It is characterized by a relatively rapid onset of action, high response and remission rates, a favorable side-effect profile, and several unique therapeutic benefits over other antidepressants. Mirtazapine has also shown promise in treating some medical disorders, including neurologic conditions, and ameliorating some of the associated debilitating symptoms of weight loss, insomnia, and postoperative nausea and vomiting.
CONCLUSIONS: Mirtazapine offers clinicians multiple therapeutic advantages especially when treating patients with comorbid medical illness.

Entities:  

Year:  2013        PMID: 24511451      PMCID: PMC3907331          DOI: 10.4088/PCC.13r01525

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN: 2155-7780


  94 in total

Review 1.  The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission.

Authors:  T de Boer
Journal:  Int Clin Psychopharmacol       Date:  1995-12       Impact factor: 1.659

2.  Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification.

Authors:  John Liappas; Thomas Paparrigopoulos; Elias Tzavellas; Andreas Rabavilas
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-11-23       Impact factor: 5.067

3.  The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period.

Authors:  M L Boshuisen; B R Slaap; E D Vester-Blokland; J A den Boer
Journal:  Int Clin Psychopharmacol       Date:  2001-11       Impact factor: 1.659

4.  Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.

Authors:  Stefano Pallanti; Leonardo Quercioli; Matteo Bruscoli
Journal:  J Clin Psychiatry       Date:  2004-10       Impact factor: 4.384

5.  Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study.

Authors:  Jerónimo Saiz-Ruiz; Jose Manuel Montes; Angela Ibáñez; Marina Díaz; Francisco Vicente; Carmelo Pelegrín; Rosa Viñas; Francisco Arias; Jose Luis Carrasco; Laura Ferrando
Journal:  Hum Psychopharmacol       Date:  2005-08       Impact factor: 1.672

6.  Mirtazapine in the treatment of essential tremor: an open-label, observer-blind study.

Authors:  Davide Uccellini; G Grampa; I La Spina; D Nasuelli; I Neromante; L Politini; F Reverberi; D Porazzi; V Carli; G Camardese
Journal:  Neuropsychiatr Dis Treat       Date:  2006-03       Impact factor: 2.570

7.  Premedication with mirtazapine reduces preoperative anxiety and postoperative nausea and vomiting.

Authors:  Chien-Chuan Chen; Chia-Shiang Lin; Yuan-Pi Ko; Yu-Chun Hung; Hsuan-Chih Lao; Yung-Wei Hsu
Journal:  Anesth Analg       Date:  2008-01       Impact factor: 5.108

8.  Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events.

Authors:  Peter de Jonge; Adriaan Honig; Joost P van Melle; Aart H Schene; Astrid M G Kuyper; Dorien Tulner; Annique Schins; Johan Ormel
Journal:  Am J Psychiatry       Date:  2007-09       Impact factor: 18.112

9.  Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy.

Authors:  Anke Rohde; Joerg Dembinski; Christoph Dorn
Journal:  Arch Gynecol Obstet       Date:  2003-06-18       Impact factor: 2.344

10.  A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients.

Authors:  O J Høyberg; B Maragakis; J Mullin; D Norum; E Stordall; P Ekdahl; E Ose; K M Moksnes; C Sennef
Journal:  Acta Psychiatr Scand       Date:  1996-03       Impact factor: 6.392

View more
  13 in total

1.  Papilledema Due to Mirtazapine.

Authors:  Mehmet Emin Ceylan; Alper Evrensel; Gökçe Cömert
Journal:  Balkan Med J       Date:  2016-05-01       Impact factor: 2.021

2.  Pharmacotherapy for Insomnia in Primary Care.

Authors:  Emily Smith; Puneet Narang; Manasa Enja; Steven Lippmann
Journal:  Prim Care Companion CNS Disord       Date:  2016-03-17

3.  Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study.

Authors:  Mahmoud Gholyaf; Vida Sheikh; Fatemeh Yasrebifar; Younes Mohammadi; Mahtabalsadat Mirjalili; Maryam Mehrpooya
Journal:  Int Urol Nephrol       Date:  2020-05-07       Impact factor: 2.370

4.  Orthorexia nervosa and comorbid depression successfully treated with mirtazapine: a case report.

Authors:  Rui Lopes; Raquel Melo; Bernardo Dias Pereira
Journal:  Eat Weight Disord       Date:  2018-08-28       Impact factor: 4.652

5.  Mirtazapine-induced hyperpigmentation with type II histopathologic findings.

Authors:  Kumar Sukhdeo; Garrett H Yoon; Lisa Rothman; Shane A Meehan; Melissa K Levin; Randie H Kim
Journal:  JAAD Case Rep       Date:  2018-11-14

6.  Mirtazapine-induced acute angle closure.

Authors:  Nilay Kahraman; Onur Durmaz; Mehmet Murat Durna
Journal:  Indian J Ophthalmol       Date:  2015-06       Impact factor: 1.848

7.  Low-Dose Mirtazapine-Induced Nightmares Necessitating its Discontinuation in a Young Adult Female.

Authors:  Vikas Menon; Pravallika Madhavapuri
Journal:  J Pharmacol Pharmacother       Date:  2017 Oct-Dec

8.  The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes.

Authors:  Abdel-Aziz Shaheen; Gilaad G Kaplan; Wagdi Almishri; Isabelle Vallerand; Alexandra D Frolkis; Scott Patten; Mark G Swain
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

9.  Evaluation of Efficacy of Mirtazapine on Pruritus and Serum Histamine and Serotonin Levels in Patients Undergoing Hemodialysis: A Before-After Pilot Clinical Trial.

Authors:  Maryam Mehrpooya; Mahmoud Gholyaf; Fatemeh Yasrebifar; Younes Mohammadi; Vida Sheikh
Journal:  Int J Nephrol Renovasc Dis       Date:  2020-05-21

10.  Comparative efficacy of placebos in short-term antidepressant trials for major depression: a secondary meta-analysis of placebo-controlled trials.

Authors:  Lisa Holper; Michael P Hengartner
Journal:  BMC Psychiatry       Date:  2020-09-07       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.